The pathology technology sector has moved incredibly quickly to develop, manufacture and supply testing devices for detecting COVID-19 infections and identifying the SARS-CoV-2 virus. Within 8 weeks of the virus becoming a significant human threat, the first commercial tests were available to detect COVID-19 infection in humans. The pathology technology suppliers are a key part of a broader ecosystem that includes the pathologist, scientists, lab staff and sample collection teams in hospital and commercial labs. It includes the community medical services where point of care testing is conducted. Of key importance in the COVID-19 example are research scientists at medical research institutes such as the Peter Doherty Centre. It is in centers like these that the basic research is completed which is often the initiator for production of commercial test products.The technology provided by Pathology Technology Australia members is critical to these research center, for without it, none of their valuable work can be done. This page aims to provide up to date information on health testing in the COVID-19 pandemic. We will cover many facets of the pathology technology so vital to testing human health in laboratories, hospitals, medical clinics and at home.
Dean Whiting on SBS News PTA was recently interview by SBS World News on testing. Head to 2.45 on clip to see CEO Dean Whiting discussing testing strategies.
TGA EXEMPTIONS We have been successful in getting the law changed; so that our companies can import and supply COVID-19 tests under the TGA exemption. I know that some of you have been concerned about the wording of the original exemption. Some of you have decided to go down the full registration route. All good, and in the end, everyone will need full registration (if you plan to keep selling after 31 Jan 2021). See this link for details.
COVID-19 POSITION STATEMENTS
PROFORMA LETTER FOR ESSENTIAL TRAVEL
Senate Select Committee submission